The CRUK MI have multiple positions in and around bioinformatics, biostatistics and computational biology.
These range from HPC and mathematical programming, through biostatistics and biomarkers, to computational biology and bioinformatics. Focuses include single cell genomics and personalised medicine in lung and prostate cancer.
For full details, please visit our website at:
Brief summaries below:
RNA Biology Group - Crispin Miller
Postdoctoral Scientist in Computational Biology:
A position is now available for a highly motivated postdoctoral research scientist to develop computational models of gene expression across populations of cells, and to ask how they change in tumours. The goal is to identify novel regulatory noncoding RNA molecules that are disrupted in cancer.
4 Year PhD Studentship:
This project will involve applying machine learning and pattern recognition techniques to high volumes of RNA-sequencing data representing a combination of single cells and bulk tissue. The scale of the data mean that novel algorithms will be required in order to achieve the volume of computation required, and this will involve programming on the latest architectures. The successful applicant will make extensive use of our on-site High Performance Computing (HPC) facility, purpose built for the analysis of cancer genomics data.
Computational Biology Team leader:
Seeking a senior computational biologist who can provide leadership to the Computational Biology Support team at the CRUK MI. They will work closely with the RNA Biology Group leader to coordinate the activities of a team providing state of the art analysis of high throughput genomics data.
Clinical and Experimental Pharmacology Group (CEP) - Caroline Dive
We are now able to isolate single Circulating Tumour Cells (CTCs) from patients’ blood samples and derive their genomic profiles utilising next generation sequencing (Hodgkinson et al Nature Medicine, June 2014). We will for the first time using advanced molecular analysis define CTC heterogeneity and examine differences in CTC genomic profiles of small cell lung cancer (SCLC) patients who are sensitive or resistant to chemotherapy, an approach that will ultimately lead to biomarker signatures for therapy selection.
2 x Postdoctoral Scientists (Biomarker Statisticians):
The successful candidates will be involved in biomarker driven clinical trial design, the development of statistical methods tailored to biomarker analysis (baseline and longitudinal data) and the analysis of resultant biomarker data with a view to optimising patient treatment.
Molecular Oncology Group - Richard Marais & CEP Group - Caroline Dive
Post-doctoral Scientist in Bioinformatics for Prostate Cancer - Prostate Cancer UK/Movember Funded:
Together with Queen’s University Belfast, we have recently been awarded a Movember Centre of Excellence for prostate cancer research.The successful candidate will join a team who will implement personalised medicine for prostate cancer. The post holder will be responsible for working with other team members to integrate genomics and proteomics data from patient samples. They will collaborate to advance the data for practical use in the personalised medicine platform and to pursue follow-up studies as appropriate.
Stem Cell Biology Group - Georges Lacaud
seeking a proactive and well-organised candidate with excellent communication and interpersonal skills to work in a dynamic laboratory undertaking cutting edge research. The successful candidate will be expected to provide expert analysis of Microarray data, Next Generation and ChIP Sequencing using a range of bioinformatics methods and resources.
About the Institute
The Cancer Research UK Manchester Institute (www.cruk.manchester.ac.uk<http://www.cruk.manchester.ac.uk>), an Institute of The University of Manchester (www.manchester.ac.uk<http://www.manchester.ac.uk>), is a world-leading centre for excellence in cancer research. The Institute is core funded by Cancer Research UK (www.cancerresearchuk.org<http://www.cancerresearchuk.org>), the largest independent cancer research organisation in the world. We are adjacent to The Christie NHS Foundation Trust (www.christie.nhs.uk<http://www.christie.nhs.uk>), one of the largest cancer treatment centres in Europe. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes. Our aim is to understand the fundamental basis of cancer and apply that knowledge to developing new treatment strategies for cancer patients. Our advanced research programmes span a spectrum of cancer research, from the molecular and cellular basis of cancer through to drug discovery, translational research and clinical trials. The Institute has outstanding laboratory facilities and exceptional core services, including next generation sequencing, microarrays, confocal microscopy, bioinformatics, histology and mass-spectrometry. We are situated in Manchester, England, a vibrant and dynamic city that is surrounded by beautiful countryside and has excellent transport links both nationally and internationally.